Clinical Trial Update: Combination of Chemopreventive Agents (All- Trans Retinoic Acid and Tamoxifen) as Potential Treatment for the Lung Complication of COVID-19 [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating a combination of all-trans retinoic acid and tamoxifen for lung complications related to COVID-19.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Covid-19-related Lung Complication

Drugs mentioned

• All-trans Retinoic Acid (all-trans retinoic acid)
• Tamoxifen (tamoxifen)

Snippet

Sponsor: Kafrelsheikh University | Conditions: the Lung Complication of COVID-19 | Phase 2 | Status: UNKNOWN